BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Gain in Phase 3 Trial

Bitget2026/10/26 09:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

BioNTech and DualityBio announced topline results from the Phase 3 DYNASTY-Breast02 breast cancer trial on October 26, 2026.
Trastuzumab pamirtecan modestly delayed disease progression versus chemotherapy in chemotherapy-naive patients with HR+/HER2-low metastatic breast cancer whose disease progressed on endocrine therapy.
Overall survival data were not mature at the interim analysis.
Interstitial lung disease occurred more frequently than in prior trials, mostly as mild or moderate cases; some cases were severe or fatal.
The partners see limited potential patient benefit in the current treatment landscape and will review the data to determine next steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260500PRIMZONEFULLFEED1001279831) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

BioNTech, DualityBio Breast Cancer Drug Shows Modest Progression-Free Survival Gain in Phase 3 Trial

You may also like

Crypto prices